The results of the new slimming drug Cagrisema that was in the test did not meet expectations.
The new slimming drug from the Danish pharmaceutical giant Novo Nordisk has turned out to be a disappointment in medical research.
Cagrisema, a new weight loss drug that was being tested, was expected to reduce the weight of the participants by 25 percent during the study. However, their weight dropped by only less than 23 percent on average.
Stock exchange rates reacted to the result by plunging twenty percent.
Novo Nordisk is known for the diabetes medicine Ozempic and Wegowy, which are used as slimming drugs.
The company has forged an uncontrollable amount of money with the help of the aforementioned slimming drugs. Novo Nordisk now has a market capitalization of more than $500 billion bigger than size Denmark’s GDP.
Novo Nordisk’s expansion into the ranks of Europe’s most valuable companies has raised fears about whether it can The same goes for Denmark as happened to Finland when Nokia’s loss cooled.